Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Alcobra Ltd.

Home Clinical Trial Sponsors and OrganizationsAlcobra Ltd.

Alcobra Ltd.

ACTIVE

Israelwww.alcobra-pharma.com/indexinvestor.cfmPrivate11–50 employeesEstablished: 2008-01-01

Part of Arcturus Therapeutics Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

5

62.5%

Phase 1

2

25.0%

Phase 3

1

12.5%

Trial Status Distribution

Completed

7

87.5%

Terminated

1

12.5%

Clinical Trials

Trials sponsored by this organization (8)

The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD

Jun 2015283 participants

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

Aug 201483 participants

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Jun 201462 participants

A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

Mar 2014300 participants

A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers

Aug 201316 participants

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

Aug 201336 participants

Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)

Feb 2011120 participants

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Oct 200943 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals
News

Back to Organizations